Lifecore Biomedical, Inc. (LFCR) |
|
6.66 -0.17 (-2.49%)
|
01-27 16:00 |
|
Open: |
6.78 |
Pre. Close: |
6.83 |
|
High:
|
6.78 |
Low:
|
6.55 |
|
Volume:
|
88,275 |
Market Cap:
|
200(M) |
|
|
|
Technical analysis |
as of: 2023-01-27 4:45:59 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 8.61 One year: 10.06 |
| Support: |
Support1: 6.49 Support2: 5.94 |
| Resistance: |
Resistance1: 7.38 Resistance2: 8.61 |
| Pivot: |
6.85  |
| Moving Average: |
MA(5): 6.81 MA(20): 6.75
MA(100): 8.2 MA(250): 9.57 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 61.5 %D(3): 63.6 |
| RSI: |
RSI(14): 43.1 |
| 52-week: |
High: 12.03 Low: 5.94 |
| Average Vol(K): |
3-Month: 78 (K) 10-Days: 67 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LFCR ] has closed above bottom band by 33.9%. Bollinger Bands are 22.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
6.78 - 6.83 |
6.83 - 6.87 |
|
Low:
|
6.46 - 6.51 |
6.51 - 6.54 |
|
Close:
|
6.59 - 6.67 |
6.67 - 6.73 |
|
Company Description |
|
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. It operates through Lifecore, Curation Foods, and Other segments. The Lifecore segment engages in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, including technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. This segment sells its non-HA products for medical use primarily in the ophthalmic, orthopedic, and other markets. The Curation Foods segment engages in processing, marketing, and selling of olive oils and wine vinegars under the O brand; and guacamole and avocado food products under the Yucatan and Cabo Fresh brands, as well as various private labels. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was incorporated in 1986 and is headquartered in Santa Maria, California. |
Headline News |
Wed, 25 Jan 2023
Moody's upgrades Crescent Energy's CFR to Ba3; rates new notes B1 - Moody's
Mon, 23 Jan 2023
Pre-Market Brief: Stocks Mixed As Investors Brace For Tech Earnings - Barchart
Thu, 12 Jan 2023
Pre-Market Brief: Stocks Move Higher Ahead of Key U.S. Inflation Data - Barchart
Wed, 11 Jan 2023
Lifecore Biomedical receives non-compliance notice from Nasdaq - Seeking Alpha
Fri, 06 Jan 2023
Pre-Market Brief: Stocks Move Higher Ahead Of Key U.S. Payrolls Data - Barchart
Thu, 05 Jan 2023
4 Cheapest Defensive Stocks You Should Think About - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
30 (M) |
| Shares Float |
19 (M) |
|
% Held by Insiders
|
1.8 (%) |
|
% Held by Institutions
|
85.3 (%) |
|
Shares Short
|
357 (K) |
|
Shares Short P.Month
|
546 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
3.26 |
|
Profit Margin (%)
|
-53.4 |
|
Operating Margin (%)
|
-5.3 |
|
Return on Assets (ttm)
|
-1.7 |
|
Return on Equity (ttm)
|
-34.9 |
|
Qtrly Rev. Growth
|
4 |
|
Gross Profit (p.s.)
|
1.7 |
|
Sales Per Share
|
6.33 |
|
EBITDA (p.s.)
|
0.32 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-27 (M) |
|
Levered Free Cash Flow
|
-25 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
-3.2 |
|
Price to Book value
|
2.03 |
|
Price to Sales
|
1.05 |
|
Price to Cash Flow
|
-7.37 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
